Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,460.40
(
-2.14%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.78
(
6.06%
)
Bitcoin
66,016.00
(
-4.03%
)
News Focus
News Focus
Post# of 19309
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122815
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DB9 post# 11712

Monday, 06/16/2008 7:49:25 PM

Monday, June 16, 2008 7:49:25 PM

Post# of 19309
>Based on these results, Pharming intends to file regulatory submissions for Rhucin® in several early launch markets in the second half of 2008 and will meet with EMEA and FDA to accelerate regulatory filings in Europe and the USA.<

“Early launch markets” is an obfuscating term. Why can’t they just state which jurisdictions they are talking about? The usual “competitive reasons” justification for reticence would not seem to apply in this case.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today